Cerebrolysin ampoules 2ml №10

Composition

1 ml solution for injection contains:
active substance: Cerebrolysin concentrate (a complex of peptides derived from the pig's brain) 215.2 mg,
excipients: sodium hydroxide; water for injections

Mechanism of action

Pharmacodynamics

Cerebrolysin contains low molecular weight biologically active neuropeptides that penetrate through the BBB and directly reach the nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.

Metabolic regulation: Cerebrolysin increases the efficiency of the aerobic energy metabolism of the brain, improves intracellular protein synthesis in the developing and aging brain.

Neuroprotection: Cerebrolysin protects neurons from the damaging effect of lactate acidosis, prevents the formation of free radicals, increases survival and prevents neuronal death under hypoxia and ischemia, reduces the damaging neurotoxic effect of excitatory amino acids (glutamate).

Neurotrophic activity: Cerebrolysin is the only nootropic peptidergic drug with proven neurotrophic activity, similar to the action of natural neuronal growth factors (NGF), but manifested under peripheral administration.

Functional neuromodulation: Cerebrolysin has a positive effect on cognitive impairment and memory processes.

Pharmacokinetics

The complex composition of the drug Cerebrolysin, the active fraction of which consists of a balanced and stable mixture of biologically active oligopeptides with a total polyfunctional effect, does not allow for the usual pharmacokinetic analysis of individual components.

Indications

• Alzheimer's disease;
• dementia syndrome of various genesis;
• chronic cerebrovascular insufficiency;
• ischemic stroke;
• traumatic injuries of the brain and spinal cord;
• mental retardation in children;
• hyperactivity and attention deficit in children;
• in complex therapy for endogenous depression resistant to antidepressants.

Contraindications

• individual intolerance to the drug;
• acute renal failure;
• epileptic status.

Side effects

Reaction to the introduction: with an excessively rapid introduction in rare cases, you may feel the heat, sweating, dizziness; in isolated cases, palpitations or arrhythmias. Therefore, the drug should be administered slowly.

On the part of the gastrointestinal tract: rarely - loss of appetite, dyspepsia, diarrhea, constipation, nausea and vomiting.

On the part of the central nervous system and peripheral nervous system: in rare cases, the alleged effect of activation was accompanied by excitation (manifested aggressive behavior, confusion, insomnia). There are reports of occurrence in isolated cases (

On the part of the immune system: extremely rare - hypersensitivity reactions or allergic reactions, manifested by headache, pain in the neck, limbs, lower back, shortness of breath, chills and collaptoid state.

Local reactions: rarely - redness of the skin, itching and burning at the injection site.

Other: extremely rare - according to the results of studies reported cases of hyperventilation, arterial hypertension, arterial hypotension, fatigue, tremor, depression, apathy, dizziness and flu-like symptoms (cough, rhinitis, respiratory tract infections).

It should be noted that some undesirable effects (agitation, arterial hypertension, hypotension, lethargy, tremor, depression, apathy, dizziness, headache, shortness of breath, diarrhea, nausea) were detected during clinical trials and occurred equally in patients treated with Cerebrolysin, and in patients of the placebo group.

Interaction

Taking into account the pharmacological profile of the drug Cerebrolysin, special attention should be paid to the possible additive effects of co-administration with antidepressants, including MAO inhibitors. In such cases, it is recommended to reduce the dose of antidepressant.

Do not mix in one solution for infusion Cerebrolysin and balanced solutions of amino acids.

Cerebrolysin is incompatible with solutions containing lipids and with solutions that change the pH of the medium (5-8).

How to take, the course of administration and dosage

Intramuscularly (up to 5 ml), intravenously (up to 10 ml), intravenously, by slow infusion (from 10 to 50 ml).

Doses and duration of treatment depend on the nature and severity of the disease, as well as on the age of the patient. You can assign single doses, the value of which can reach 50 ml, but more preferably a course of treatment. The recommended optimal course of treatment is daily injections for 10–20 days.

Acute conditions (ischemic stroke, TBI, complications after neurosurgical operations) - from 10 to 50 ml.

The residual period of cerebral stroke and traumatic injury of the brain and spinal cord is from 5 to 50 ml.

Psychoorganic syndrome and depression - from 5 to 30 ml.

Alzheimer's disease, dementia of vascular and combined Alzheimer's-vascular genesis - from 5 to 30 ml.

In neuropediatric practice - 0.1-0.2 ml / kg.

To improve the effectiveness of treatment, repeated courses may be conducted, until the patient's condition is improved due to treatment. After the first course, the frequency of dose can be reduced to 2 or 3 times a week.

Doses from 10 to 50 ml are recommended to be administered only through slow intravenous infusions after dilution with the proposed standard solutions for infusions. The duration of infusion is from 15 to 60 minutes.

Special notes

Compatibility of the drug was tested and confirmed (for 24 hours at room temperature and the presence of light) with the following standard solutions for infusions:

- 0.9% solution of sodium chloride (9 mg NaCl / ml);

- Ringer's solution (Na + - 153.98 mmol / l; Ca2 + - 2.74 mmol / l; K + - 4.02 mmol / l; Cl- - 163.48 mmol / l).

- 5% glucose solution.

Simultaneous prescription of the drug Cerebrolysin with Vitamins and drugs that improve cardiac circulation is allowed, but these drugs should not be mixed in the same syringe with the drug Cerebrolysin. Use only a clear solution and only once.

Influence on ability to drive vehicles and work with mechanisms. Clinical trials have shown that Cerebrolysin does not affect the ability to drive and use machinery.

Storage conditions

The drug should be stored in a dark place at a temperature no higher than 25 ° C.